Clinical Practice Experience with Avelumab First-Line Maintenance in Urothelial Carcinoma

Daniel Petrylak, MD and Donald Barry Boyd, MD, MS, examine real-world data presented in the recent publication, “Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.”

Drs Donald Barry Boyd and Daniel Petrylak consider the advantages and disadvantages of checkpoint inhibitor maintenance therapy in advanced urothelial carcinoma.

Experts discuss the changing field of advanced urothelial carcinoma and consider sequencing of therapy.

Genitourinary oncology experts discuss clinical trials of maintenance therapy for urothelial carcinoma and their clinical impacts.

Daniel Petrylak, MD, and Donald Barry Boyd, MD, MS, review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.